Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Biotechnology

Healthcare
$92.49 +3.81%

+$3.89 today

Market cap
$6.04B
Beta
0.51
P/E (TTM)
-7.8
EPS (TTM)
-$13.57
52W Low $47.89High $114.99

Volume 0.50M

Average 0.95M

MIRM Interest Expense

Cost of servicing the company's debt during the period.

Mirum Pharmaceuticals, Inc.NASDAQ: MIRM

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense declines year over year

Q2 FY2026 interest expense of $2.62M fell 27.1% year over year, behind the -6.4% change in trailing-twelve-month interest expense. Sequentially, it fell 27.6% from the prior quarter. Over 3 fiscal years it compounded at -3.4% a year.

Context

  • Interest expense amounted to 2.8% of revenue in FY2025, down 1.5 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -27.1% toward the trailing-twelve-month pace of -6.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.62M-27.6% QoQ
Last fiscal yearDec 2025
$14.39M+0.5% YoY
LTMJun 2026
$13.44M-6.4% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.1%——
1 year+0.5%——
3-year CAGR-3.4%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
14.39M USD
Year-over-year change
+0.5%
4-year CAGR
-4.9%

Interest Expense vs competitors

How MIRM compares with its peers on the latest reported figures

  • MIRM's LTM Jun 2026 interest expense of $13.44M is the 3rd highest of the 8 companies compared; the peer median is $4.59M.
  • Its year-over-year change of -6.4% is the 5th highest of 6, against a peer median of +20.8%.
  • Interest expense amounts to 2.2% of revenue for MIRM, versus a peer median of 2.5%.
MIRM Competitors Peer median
Interest Expense for MIRM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$68.19M +10.8%+13.0%10.2%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$31.51M +129.3%+77.9%2.5%
MIRMMirum Pharmaceuticals, Inc.LTM Jun 2026$13.44M -6.4%-3.4%2.2%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$10.4M +20.8%—15.0%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$4.59M -59.3%-0.8%0.7%
ALTAltimmune, Inc.LTM Mar 2026$2.7M +29933.3%+489.2%7508.3%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding MIRM) $4.59M+20.8%+45.4%2.5%

Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue19.14M77.06M186.37M336.89M521.31M
Cost of Revenue1.9M12.37M47.04M81.64M100.58M
Gross Profit17.24M64.69M139.34M255.25M420.73M
Gross Margin90.1%83.9%74.8%75.8%80.7%
Research & Development131.43M106.84M102.61M140.63M186.18M
Selling, General & Admin59.22M89.07M145.88M202.22M257.03M
Operating Expenses190.65M195.91M248.49M342.85M443.21M
Depreciation & Amortization975K3.24M10.83M23.63M24.24M
EBITDA(65.39M)(122.85M)(136.49M)(48.97M)17.21M
EBITDA Margin-341.7%-159.4%-73.2%-14.5%3.3%
Operating Income(173.41M)(131.22M)(109.15M)(87.61M)(22.14M)
Operating Margin-906.1%-170.3%-58.6%-26.0%-4.2%
Interest Income366K3.86M13.74M13.79M12.73M
Interest Expense17.59M15.98M15.11M14.31M14.39M
Other Income / Expenses89.46M(10.85M)(53.27M)694K709K
Income Before Tax(83.95M)(142.07M)(162.42M)(86.91M)(21.43M)
Pre-Tax Margin-438.7%-184.4%-87.1%-25.8%-4.1%
Income Tax Expense37K(6.41M)991K1.03M1.94M
Net Income(83.99M)(135.67M)(163.42M)(87.94M)(23.36M)
Net Margin-438.9%-176.0%-87.7%-26.1%-4.5%
EPS (Basic)(2.77)(4.01)(4.00)(1.85)(0.47)
EPS (Diluted)(2.77)(4.02)(4.00)(1.85)(0.47)
Weighted Avg Shares30.32M33.84M40.89M47.52M50.2M
Weighted Avg Shares (Diluted)30.32M33.98M40.89M47.52M50.2M

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Intrinsic Alpha fair value

Locked

Current Price

$92.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.